Page last updated: 2024-11-13
4-acetylantroquinonol b
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4-acetylantroquinonol B: an antineoplastic agent isolated from Antrodia connamomea; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 112500518 |
SCHEMBL ID | 19886003 |
MeSH ID | M0553563 |
Synonyms (9)
Synonym |
---|
SCHEMBL19886003 |
4-acetylantroquinonol b |
4-aaqb |
4-acetyl antroquinonol b |
1187652-02-3 |
72xzo87czj , |
unii-72xzo87czj |
DTXSID601099832 |
(3s,5r)-5-[(2e,6e)-8-[(1r,2r,6r)-2-(acetyloxy)-3,4-dimethoxy-6-methyl-5-oxo-3-cyclohexen-1-yl]-2,6-dimethyl-2,6-octadien-1-yl]dihydro-3-methyl-2(3h)-furanone |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" The protein levels of p53 and p21 proteins were also increased when the cells were treated with low dosage (0." | ( 4-acetylantroquinonol B isolated from Antrodia cinnamomea arrests proliferation of human hepatocellular carcinoma HepG2 cell by affecting p53, p21 and p27 levels. Chiang, BH; Lin, YW, 2011) | 1.81 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (15)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 10 (66.67) | 24.3611 |
2020's | 5 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.60
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.60) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |